NSRX — Nasus Pharma Ltd.

Is NSRX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - General

Strong Oversold As of November 17, 2026

Nasus Pharma Ltd. (NSRX) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $2.66. The rating moved from Oversold to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Nasus Pharma Ltd. (NSRX) is a small, thinly covered healthcare issuer with limited publicly available financial and clinical detail in the supplied materials. The broader market is favoring large-cap pharmaceutical names and defensive exposure, which constrains demand for micro-cap biotech equities absent clear, near-term catalysts. Key potential upside drivers would be positive clinical readouts, regulatory progress, or a licensing/partnership deal; conversely, short cash runway, dilutive financings and trial/regulatory setbacks are primary downside risks. Given lack of company-specific transparency and elevated idiosyncratic risk, near-term moves are likely to be catalyst-driven and volatile.

Key factors

  • Very limited publicly available company-specific financial and clinical data in the provided inputs; visibility is low
  • Small-cap / micro-cap profile implied by limited coverage increases sensitivity to funding, dilution and single-catalyst outcomes
  • Healthcare sector environment favors large-cap pharma and defensive flows, which may limit near-term investor appetite for smaller biotech stories
  • Potential upside catalysts typical for a company of this type: clinical data readouts, regulatory progress, licensing or partnership announcements
  • Convertible-debt and broader biotech financing dynamics raise the likelihood of dilution for mid/small-cap issuers in the current market
  • No clear short-term macro or geopolitical shocks in the market summary, which supports stable risk-on sentiment for selective names

Risks

  • Severely limited public filings and reporting in the provided dataset — inability to confirm cash runway, revenue profile, or upcoming milestone timing
  • High dilution risk from equity raises or convertible financings if cash runway is short
  • Clinical or regulatory setbacks that could materially depress valuation for a single-program company
  • Competitive pressure from larger pharma entrants and approved products (sector trend toward large-cap outperformance)
  • Low liquidity and wide bid-ask spreads common to micro-cap stocks, amplifying volatility and execution risk
  • Absence of social/research coverage reduces retail momentum and increases dependence on formal catalysts

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for NSRX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.